Comparison · NCT01215253-ddc645e1
Ranolazine vs Placebo: Number of Patients With Ventricular Tachycardia (VT) or Ventricular Fibrillation (VF) or Death
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ranolazine vs Placebo: Number of Patients With Ventricular Tachycardia (VT) or Ventricular Fibrillation (VF) or Death. Trial comparisons, record NCT01215253-ddc645e1. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01215253-ddc645e1
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.341 | 0.301 | 0.383 | wilson | |
| Risk in group 2 | 0.394 | 0.353 | 0.438 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0532 | -0.112 | 0.00615 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.865 | 0.736 | 1.02 | log | |
| Odds ratio, group 1 over group 2 | 0.795 | 0.616 | 1.03 | log | |
| Number needed to treat, for one fewer participant with the outcome on Ranolazine than on Placebo | 18.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ranolazine | At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at end of first week. For patients on anti-arrhythmic therapy at the time of randomization, their ECG will be checked at end of first week on 500 mg dose and again at end of second week on 1000 mg dose. For patients with CrCl \<60ml/min prior to randomization, their CrCl will be checked again at 2 weeks and study drug discontinued if \<30ml/min. For patients with CrCl \<60ml/min at 2 weeks, their CrCl will be checked again at 4 weeks and study drug discontinued if \<30ml/min.~Ranolazine: At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at beginning of second week. | 174 | 510 | OG000 |
| Group 2 | Placebo | Ranolazine: At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at beginning of second week. | 198 | 502 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Patients With Ventricular Tachycardia (VT) or Ventricular Fibrillation (VF) or Death
- Description
Primary endpoint of the study will be defined as a composite endpoint consisting of Ventricular Tachycardia or Ventricular Fibrillation requiring antitachycardia pacing (ATP) therapy, implantable cardioverter-defibrillator (ICD) shock, or death, whichever occurs first.
- Time frame
- 2 years of follow-up on average
- Population
- This outcome measure was an intent-to-treat analysis therefore all randomized subjects were included.
Source ClinicalTrials.gov
Trial
- Title
- Ranolazine Implantable Cardioverter-Defibrillator Trial
- NCT number
- NCT01215253
- Phases
- PHASE3
- Conditions
- Ischemic Cardiomyopathy, Nonischemic Cardiomyopathy, Heart Failure
- Interventions
- Ranolazine
- Lead sponsor
- University of Rochester
- Results first posted
- 2018-06-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01215253?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01215253-ddc645e1